CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Files An 8-K Submission of Matters to a Vote of Security Holders

On October 16, 2019, Champion’s Oncology, Inc. (the “Company”) held its Annual Meeting of the Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows, there being no broker non-votes for any matter:

1. Election of Directors.>The seven director nominees named in the Company\’s 2019 proxy statement were elected to serve for a one-year term expiring at the 2020 Annual Meeting of the Stockholders or until their successors are duly elected and qualified, based upon the following votes:

2. Ratification of Appointment of Independent Registered Accounting Firm.>The appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2020, was ratified as follows:

3. Advisory Vote of the Compensation of the Company’s Named Executive Officers.>The proposal to approve, on an advisory basis, the compensation of the Company\’s named executive officers, as described in the Company\’s 2019 proxy statement, was approved by the following votes:

4. Advisory Vote on the Frequency of Stockholder Votes on Executive Compensation.>The proposal to approve, on an advisory basis, a one-year frequency of the stockholder votes in the compensation of the Company\’s named executive officers, was approved by the following votes:

About CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR)

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank.